© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
CARGO Therapeutics, Inc. Common Stock (CRGX) stock remained unchanged at $4.47 a share on NASDAQ. The stock opened at $4.47, fluctuating between $4.47 to $4.47 during the session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2025 | 4.53 | 4.53 | 4.46 | 4.47 | 10.83M |
| Aug 15, 2025 | 4.46 | 4.57 | 4.46 | 4.54 | 1.61M |
| Aug 14, 2025 | 4.46 | 4.50 | 4.46 | 4.46 | 453.64K |
| Aug 13, 2025 | 4.46 | 4.47 | 4.45 | 4.46 | 1.35M |
| Aug 12, 2025 | 4.47 | 4.49 | 4.45 | 4.46 | 1.81M |
| Aug 11, 2025 | 4.50 | 4.51 | 4.47 | 4.48 | 2.42M |
| Aug 08, 2025 | 4.47 | 4.50 | 4.46 | 4.49 | 1.25M |
| Aug 07, 2025 | 4.46 | 4.49 | 4.46 | 4.48 | 985.27K |
| Aug 06, 2025 | 4.47 | 4.47 | 4.46 | 4.46 | 602.94K |
| Aug 05, 2025 | 4.49 | 4.49 | 4.45 | 4.46 | 718.04K |
| Aug 04, 2025 | 4.50 | 4.50 | 4.46 | 4.48 | 587.12K |
| Aug 01, 2025 | 4.47 | 4.50 | 4.45 | 4.49 | 673.48K |
| Jul 31, 2025 | 4.47 | 4.51 | 4.45 | 4.47 | 991.7K |
| Jul 30, 2025 | 4.49 | 4.52 | 4.45 | 4.47 | 1.75M |
| Jul 29, 2025 | 4.50 | 4.51 | 4.48 | 4.49 | 1.38M |
| Jul 28, 2025 | 4.53 | 4.53 | 4.50 | 4.50 | 1.26M |
| Jul 25, 2025 | 4.52 | 4.56 | 4.50 | 4.52 | 1.12M |
| Jul 24, 2025 | 4.48 | 4.55 | 4.47 | 4.52 | 1.25M |
| Jul 23, 2025 | 4.54 | 4.54 | 4.46 | 4.48 | 2.36M |
| Jul 22, 2025 | 4.49 | 4.49 | 4.40 | 4.49 | 7.72M |
CARGO Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering innovative chimeric antigen receptor (CAR) T-cell therapies for patients battling cancer. Its primary therapeutic candidate is CRG-022, an autologous CD22 CAR T-cell product. This therapy is specifically engineered to counteract mechanisms of resistance in B-cell malignancies by targeting CD22, a distinct tumor antigen prevalent in these conditions. The company's pipeline also includes CRG-023, a novel tri-specific CAR T product candidate designed to engage tumor cells through three different B-cell antigen targets. Formerly known as Syncopation Life Sciences, Inc., the company adopted its current name, CARGO Therapeutics, Inc., in September 2022. Established in 2019, CARGO Therapeutics is headquartered in San Mateo, California.
| Employees | 167 |
| Beta | 0.29 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |